512 related articles for article (PubMed ID: 15904505)
1. Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi.
Kadhiravan T; Wig N; Kapil A; Kabra SK; Renuka K; Misra A
BMC Infect Dis; 2005 May; 5():37. PubMed ID: 15904505
[TBL] [Abstract][Full Text] [Related]
2. Novel restriction enzyme SSiI for the detection of mutation in GyrA gene of Salmonella enterica serovar Typhi.
Agrawal P; Kapila K; Kumar S; Ghosh AN; Maurya AK
Indian J Pathol Microbiol; 2010; 53(3):509-12. PubMed ID: 20699513
[TBL] [Abstract][Full Text] [Related]
3. Treatment failure in a typhoid patient infected with nalidixic acid resistant S. enterica serovar Typhi with reduced susceptibility to ciprofloxacin: a case report from Cameroon.
Nkemngu NJ; Asonganyi ED; Njunda AL
BMC Infect Dis; 2005 Jun; 5():49. PubMed ID: 15969764
[TBL] [Abstract][Full Text] [Related]
4. Emergence of highly fluoroquinolone-resistant Salmonella enterica serovar Typhi in a community-based fever surveillance from Kolkata, India.
Dutta S; Sur D; Manna B; Sen B; Bhattacharya M; Bhattacharya SK; Wain J; Nair S; Clemens JD; Ochiai RL
Int J Antimicrob Agents; 2008 Apr; 31(4):387-9. PubMed ID: 18280709
[No Abstract] [Full Text] [Related]
5. Typhoid fever due to multiresistant Salmonella enterica serovar typhi having reduced susceptibility to ciprofloxacin and nalidixic acid resistance.
Panhotra BR; Saxena AK; Al-Ghamdi AM
Saudi Med J; 2004 Oct; 25(10):1509-11. PubMed ID: 15494840
[No Abstract] [Full Text] [Related]
6. [A case of Salmonella enterica serovar typhi with decreased susceptibility to ciprofloxacin].
Gaborieau V; Weill FX; Marchou B
Med Mal Infect; 2010 Dec; 40(12):691-5. PubMed ID: 20724089
[TBL] [Abstract][Full Text] [Related]
7. Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin--an emerging problem in Bangladesh.
Rahman MM; Haq JA; Morshed MA; Rahman MA
Int J Antimicrob Agents; 2005 Apr; 25(4):345-6. PubMed ID: 15784317
[No Abstract] [Full Text] [Related]
8. In vitro efficacy of the combination of ciprofloxacin and cefotaxime against nalidixic acid-resistant Salmonella enterica serotype Typhi.
Kim DM; Neupane GP; Jang SJ; Kim SH; Lee BK
Int J Antimicrob Agents; 2010 Aug; 36(2):155-8. PubMed ID: 20478696
[TBL] [Abstract][Full Text] [Related]
9. Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series.
Slinger R; Desjardins M; McCarthy AE; Ramotar K; Jessamine P; Guibord C; Toye B
BMC Infect Dis; 2004 Sep; 4():36. PubMed ID: 15380025
[TBL] [Abstract][Full Text] [Related]
10. Nalidixic acid-resistant Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin caused treatment failure: a report from Bangladesh.
Asna SM; Haq JA; Rahman MM
Jpn J Infect Dis; 2003 Feb; 56(1):32-3. PubMed ID: 12711825
[No Abstract] [Full Text] [Related]
11. Effectiveness of treatment regimens for Typhoid fever in the nalidixic acid-resistant S. typhi (NARST) era in South India.
Bandyopadhyay R; Balaji V; Yadav B; Jasmine S; Sathyendra S; Rupali P
Trop Doct; 2018 Jul; 48(3):182-188. PubMed ID: 29495943
[TBL] [Abstract][Full Text] [Related]
12. Nalidixic acid screening test for the detection of decreased susceptibility to ciprofloxacin in Salmonella typhi.
Ciraj AM; Seema DS; Bhat GK; Shivananda PG
Indian J Pathol Microbiol; 2001 Oct; 44(4):407-8. PubMed ID: 12035350
[No Abstract] [Full Text] [Related]
13. Treatment failure in typhoid fever with ciprofloxacin susceptible Salmonella enterica serotype Typhi.
Rupali P; Abraham OC; Jesudason MV; John TJ; Zachariah A; Sivaram S; Mathai D
Diagn Microbiol Infect Dis; 2004 May; 49(1):1-3. PubMed ID: 15135492
[TBL] [Abstract][Full Text] [Related]
14. Re-emerging chloramphenicol sensitivity and emerging low level ciprofloxacin resistance among Salmonella enterica serotype typhi isolates in North India.
Gupta V; Kaur J; Kaistha N
Trop Doct; 2009 Jan; 39(1):28-30. PubMed ID: 19211419
[TBL] [Abstract][Full Text] [Related]
15. Emergence of multidrug-resistant Salmonella enterica serovar Typhi with reduced susceptibility to fluoroquinolones in Cambodia.
Kasper MR; Sokhal B; Blair PJ; Wierzba TF; Putnam SD
Diagn Microbiol Infect Dis; 2010 Feb; 66(2):207-9. PubMed ID: 19800753
[TBL] [Abstract][Full Text] [Related]
16. High level of resistance to nalidixic acid in Salmonella enterica serovar Typhi in Central India.
Kumar Y; Sharma A; Mani KR
J Infect Dev Ctries; 2009 Jul; 3(6):467-9. PubMed ID: 19762961
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistant Salmonella typhi in Rourkela, Orissa.
Das U; Bhattacharya SS
Indian J Pathol Microbiol; 2000 Apr; 43(2):135-8. PubMed ID: 11217269
[TBL] [Abstract][Full Text] [Related]
18. Low-level quinolone-resistance in multi-drug resistant typhoid.
Mirza SH; Khan MA
J Coll Physicians Surg Pak; 2008 Jan; 18(1):13-6. PubMed ID: 18452661
[TBL] [Abstract][Full Text] [Related]
19. Typhoid fever in the United States, 1999-2006.
Lynch MF; Blanton EM; Bulens S; Polyak C; Vojdani J; Stevenson J; Medalla F; Barzilay E; Joyce K; Barrett T; Mintz ED
JAMA; 2009 Aug; 302(8):859-65. PubMed ID: 19706859
[TBL] [Abstract][Full Text] [Related]
20. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae.
Crump JA; Barrett TJ; Nelson JT; Angulo FJ
Clin Infect Dis; 2003 Jul; 37(1):75-81. PubMed ID: 12830411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
